GTx, Inc. (NASDAQ:GTXI) Chairman Robert James Wills purchased 5,000 shares of the stock in a transaction dated Tuesday, June 26th. The shares were acquired at an average price of $16.75 per share, with a total value of $83,750.00. Following the completion of the acquisition, the chairman now owns 137,344 shares in the company, valued at approximately $2,300,512. The acquisition was disclosed in a document filed with the SEC, which can be accessed through this hyperlink.
Shares of GTX stock opened at $16.92 on Wednesday. GTx, Inc. has a 12 month low of $4.45 and a 12 month high of $23.40. The stock has a market cap of $380.75 million, a P/E ratio of -9.67 and a beta of 1.58.
GTX (NASDAQ:GTXI) last announced its earnings results on Tuesday, May 15th. The biopharmaceutical company reported ($0.62) EPS for the quarter, missing analysts’ consensus estimates of ($0.43) by ($0.19). equities analysts anticipate that GTx, Inc. will post -1.87 earnings per share for the current fiscal year.
GTXI has been the subject of a number of research analyst reports. Robert W. Baird reiterated a “buy” rating and set a $20.00 price target on shares of GTX in a report on Tuesday, March 6th. ValuEngine upgraded GTX from a “hold” rating to a “buy” rating in a report on Monday, April 2nd. BidaskClub cut GTX from a “strong-buy” rating to a “buy” rating in a report on Wednesday, March 21st. Stifel Nicolaus increased their price target on GTX from $16.00 to $45.00 and gave the stock a “buy” rating in a report on Monday, March 5th. Finally, Zacks Investment Research cut GTX from a “hold” rating to a “sell” rating in a report on Friday, May 18th. One analyst has rated the stock with a sell rating, one has issued a hold rating, two have issued a buy rating and one has issued a strong buy rating to the stock. The stock presently has an average rating of “Buy” and a consensus price target of $37.50.
A number of institutional investors have recently made changes to their positions in GTXI. GSA Capital Partners LLP acquired a new stake in GTX in the 1st quarter valued at about $197,000. Element Capital Management LLC acquired a new stake in GTX in the 1st quarter valued at about $234,000. Northern Trust Corp raised its position in GTX by 23.9% in the 1st quarter. Northern Trust Corp now owns 18,705 shares of the biopharmaceutical company’s stock valued at $332,000 after purchasing an additional 3,605 shares in the last quarter. EAM Investors LLC acquired a new stake in GTX in the 4th quarter valued at about $551,000. Finally, Millennium Management LLC acquired a new stake in GTX in the 4th quarter valued at about $749,000. Institutional investors own 22.66% of the company’s stock.
GTx, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of medicines for the treatment of stress urinary incontinence (SUI) and prostate cancer. It focuses on the development of selective androgen receptor modulators (SARMs) for the treatment of breast cancer, SUI, and Duchenne muscular dystrophy; and selective androgen receptor degraders to treat progressive castration-resistant prostate cancer.
Receive News & Ratings for GTX Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for GTX and related companies with MarketBeat.com's FREE daily email newsletter.